Dianthus Therapeutics, Inc.
$91.92
▲
1.7%
2026-04-21 06:27:04
dianthustx.com
NCM: DNTH
Explore Dianthus Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$5 B
Current Price
$91.92
52W High / Low
$96.5 / $16.64
Stock P/E
—
Book Value
$11.41
Dividend Yield
—
ROCE
-35.57%
ROE
-38.38%
Face Value
—
EPS
$-4.2
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
92
Beta
0.21
Debt / Equity
0.28
Current Ratio
13.32
Quick Ratio
13.32
Forward P/E
-17.55
Price / Sales
2,400.72
Enterprise Value
$3.59 B
EV / EBITDA
-20.18
EV / Revenue
1,762.9
Rating
Strong Buy
Target Price
$125.46
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | BeyondSpring Inc. | $1.78 | — | $73 M | — | -72.39% | 3.09% | $3.44 / $1.21 | $-0.8 |
| 2. | Orchestra BioMed Holdings, Inc. | $4.35 | — | $268.03 M | — | -52.8% | -1.09% | $5.42 / $2.2 | $0.94 |
| 3. | Cadrenal Therapeutics, Inc. | $5.25 | — | $13.09 M | — | -491.51% | -2.6% | $17.5 / $4.21 | $1.17 |
| 4. | Denali Therapeutics Inc. | $20.54 | — | $3.26 B | — | -53.07% | -45.69% | $23.77 / $12.31 | $6.49 |
| 5. | Korro Bio, Inc. | $14.28 | — | $207.54 M | — | -85.99% | -1.11% | $55.89 / $5.2 | $5.46 |
| 6. | NeuroSense Therapeutics Ltd. | $0.71 | — | $25.1 M | — | -383.35% | -21.75% | $2.6 / $0.63 | $-0.05 |
| 7. | MannKind Corporation | $2.92 | 135.49 | $907.36 M | — | 7.49% | -9.03% | $6.51 / $2.23 | $-0.17 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 0.28 M | 0.4 M | 0.19 M | 1.16 M | 1.33 M |
| Operating Profit | -69.54 M | -40.29 M | -34.93 M | -33.18 M | -31.92 M |
| Net Profit | -64.43 M | -36.77 M | -31.63 M | -29.51 M | -28.44 M |
| EPS in Rs | -1.18 | -0.68 | -0.58 | -0.54 | -0.52 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 2.04 M | 6.24 M | 2.83 M | 6.42 M |
| Operating Profit | -177.93 M | -101.86 M | -48.17 M | -29.7 M |
| Net Profit | -162.34 M | -84.97 M | -43.55 M | -28.48 M |
| EPS in Rs | -2.98 | -1.56 | -0.8 | -0.52 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 530.92 M | 374.01 M | 179.41 M | 83.11 M |
| Total Liabilities | 37.52 M | 21.53 M | 10.54 M | 9.45 M |
| Equity | 493.4 M | 352.48 M | 168.87 M | 73.66 M |
| Current Assets | 409.44 M | 280.9 M | 177.45 M | 82.03 M |
| Current Liabilities | 30.73 M | 18.45 M | 9.63 M | 8.22 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -129.06 M | -78.18 M | -36.86 M | -29.07 M |
| Investing CF | -122.83 M | -286.81 M | 20.25 M | -59.82 M |
| Financing CF | 280.12 M | 255.62 M | 133.57 M | 96.68 M |
| Free CF | -129.27 M | -78.28 M | -36.97 M | -29.21 M |
| Capex | -0.21 M | -0.1 M | -0.11 M | -0.14 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 120.63% | -55.96% | — | — |
| Earnings Growth % | -95.08% | -52.95% | — | — |
| Profit Margin % | -1362.77% | -1541.22% | -443.76% | — |
| Operating Margin % | -1633.74% | -1704.67% | -462.91% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -1627.14% | -1692.11% | -460.62% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.